Literature DB >> 27469514

An Illustration of Inverse Probability Weighting to Estimate Policy-Relevant Causal Effects.

Jessie K Edwards, Stephen R Cole, Catherine R Lesko, W Christopher Mathews, Richard D Moore, Michael J Mugavero, Daniel Westreich.   

Abstract

Traditional epidemiologic approaches allow us to compare counterfactual outcomes under 2 exposure distributions, usually 100% exposed and 100% unexposed. However, to estimate the population health effect of a proposed intervention, one may wish to compare factual outcomes under the observed exposure distribution to counterfactual outcomes under the exposure distribution produced by an intervention. Here, we used inverse probability weights to compare the 5-year mortality risk under observed antiretroviral therapy treatment plans to the 5-year mortality risk that would had been observed under an intervention in which all patients initiated therapy immediately upon entry into care among patients positive for human immunodeficiency virus in the US Centers for AIDS Research Network of Integrated Clinical Systems multisite cohort study between 1998 and 2013. Therapy-naïve patients (n = 14,700) were followed from entry into care until death, loss to follow-up, or censoring at 5 years or on December 31, 2013. The 5-year cumulative incidence of mortality was 11.65% under observed treatment plans and 10.10% under the intervention, yielding a risk difference of -1.57% (95% confidence interval: -3.08, -0.06). Comparing outcomes under the intervention with outcomes under observed treatment plans provides meaningful information about the potential consequences of new US guidelines to treat all patients with human immunodeficiency virus regardless of CD4 cell count under actual clinical conditions.
© The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; antiretroviral therapy; causal inference; epidemiologic methods; intervention studies; policy; treatment guidelines

Mesh:

Substances:

Year:  2016        PMID: 27469514      PMCID: PMC4983650          DOI: 10.1093/aje/kwv339

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  56 in total

1.  Doubly robust estimation of the generalized impact fraction.

Authors:  Masataka Taguri; Yutaka Matsuyama; Yasuo Ohashi; Akiko Harada; Hirotsugu Ueshima
Journal:  Biostatistics       Date:  2011-11-13       Impact factor: 5.899

2.  Splines for trend analysis and continuous confounder control.

Authors:  Chanelle J Howe; Stephen R Cole; Daniel J Westreich; Sander Greenland; Sonia Napravnik; Joseph J Eron
Journal:  Epidemiology       Date:  2011-11       Impact factor: 4.822

3.  When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data.

Authors:  Lauren E Cain; James M Robins; Emilie Lanoy; Roger Logan; Dominique Costagliola; Miguel A Hernán
Journal:  Int J Biostat       Date:  2010       Impact factor: 0.968

4.  Structural mean models for compliance analysis in randomized clinical trials and the impact of errors on measures of exposure.

Authors:  Els Goetghebeur; Vansteelandt Stijn
Journal:  Stat Methods Med Res       Date:  2005-08       Impact factor: 3.021

Review 5.  A history of the population attributable fraction and related measures.

Authors:  Charles Poole
Journal:  Ann Epidemiol       Date:  2014-12-11       Impact factor: 3.797

6.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

7.  The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death.

Authors:  Daniel Westreich; Stephen R Cole; Jessica G Young; Frank Palella; Phyllis C Tien; Lawrence Kingsley; Stephen J Gange; Miguel A Hernán
Journal:  Stat Med       Date:  2012-04-11       Impact factor: 2.373

8.  Time scale and adjusted survival curves for marginal structural cox models.

Authors:  Daniel Westreich; Stephen R Cole; Phyllis C Tien; Joan S Chmiel; Lawrence Kingsley; Michele Jonsson Funk; Kathryn Anastos; Lisa P Jacobson
Journal:  Am J Epidemiol       Date:  2010-02-05       Impact factor: 4.897

9.  Hypertension and low HDL cholesterol were associated with reduced kidney function across the age spectrum: a collaborative study.

Authors:  Michelle C Odden; Ira B Tager; Ron T Gansevoort; Stephan J L Bakker; Linda F Fried; Anne B Newman; Ronit Katz; Suzanne Satterfield; Tamara B Harris; Mark J Sarnak; David Siscovick; Michael G Shlipak
Journal:  Ann Epidemiol       Date:  2013-01-10       Impact factor: 3.797

10.  When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

Authors:  Lauren E Cain; Roger Logan; James M Robins; Jonathan A C Sterne; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; Ard van Sighem; Frank de Wolf; Heiner C Bucher; Viktor von Wyl; Anna Esteve; Jordi Casabona; Julia del Amo; Santiago Moreno; Remonie Seng; Laurence Meyer; Santiago Perez-Hoyos; Roberto Muga; Sara Lodi; Emilie Lanoy; Dominique Costagliola; Miguel A Hernan
Journal:  Ann Intern Med       Date:  2011-04-19       Impact factor: 25.391

View more
  4 in total

Review 1.  Measurement Error and Environmental Epidemiology: a Policy Perspective.

Authors:  Jessie K Edwards; Alexander P Keil
Journal:  Curr Environ Health Rep       Date:  2017-03

2.  Targeted maximum likelihood estimation of causal effects with interference: A simulation study.

Authors:  Paul N Zivich; Michael G Hudgens; Maurice A Brookhart; James Moody; David J Weber; Allison E Aiello
Journal:  Stat Med       Date:  2022-07-18       Impact factor: 2.497

3.  Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA).

Authors:  Souvik Mitra; Amish Jain; Joseph Y Ting; Nadya Ben Fadel; Christine Drolet; Ayman Abou Mehrem; Amuchou Soraisham; Bonny Jasani; Deepak Louis; Anie Lapointe; Jon Dorling; Faiza Khurshid; Abbas Hyderi; Kumar Kumaran; Jaya Bodani; Dany Weisz; Ruben Alvaro; Mohammed Adie; Miroslav Stavel; Alyssa Morin; Soume Bhattacharya; Jaideep Kanungo; Rody Canning; Xiang Y Ye; Tara Hatfield; Courtney E Gardner; Prakesh Shah
Journal:  BMJ Open       Date:  2021-05-05       Impact factor: 2.692

4.  Refining the Association Between Body Mass Index and Atrial Fibrillation: G-Formula and Restricted Mean Survival Times.

Authors:  Sarah C Conner; Sara Lodi; Kathryn L Lunetta; Juan P Casas; Steven A Lubitz; Patrick T Ellinor; Christopher D Anderson; Qiuxi Huang; Justin Coleman; Wendy B White; Emelia J Benjamin; Ludovic Trinquart
Journal:  J Am Heart Assoc       Date:  2019-08-08       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.